21 results on '"Riccardi, Carlo"'
Search Results
2. Role of histamine H4 receptor in the anti-inflammatory pathway of glucocorticoid-induced leucin zipper (GILZ) in a model of lung fibrosis.
- Author
-
Sgambellone, Silvia, Febo, Marta, Durante, Mariaconcetta, Marri, Silvia, Villano, Serafina, Bereshchenko, Oxana, Migliorati, Graziella, Masini, Emanuela, Riccardi, Carlo, Bruscoli, Stefano, and Lucarini, Laura
- Subjects
PULMONARY fibrosis ,HISTAMINE receptors ,HISTAMINERGIC mechanisms ,AIR resistance ,AIRWAY resistance (Respiration) ,INSUFFLATION - Abstract
Introduction: This study investigates the interactions between histaminergic system and glucocorticoid-induced leucin zipper (GILZ) in the inflammatory process and glucocorticoid modulation in lung fibrosis. Methods: Wild-type (WT) and GILZ Knock-Out (KO) mice were treated with bleomycin (0.05 IU) or saline, delivered by intra-tracheal injection. After surgery, mice received a continuous infusion of JNJ7777120 (JNJ, 2 mg/kg b.wt.) or vehicle for 21 days. Lung function was studied by measuring airway resistance to air insufflation through the analysis of pressure at airway opening (PAO). Lung samples were collected to evaluate the expression of histamine H
4 R, Anx-A1, and p65-NF-kB, the activity of myeloperoxidase (MPO), and the production of pro-inflammatory cytokines. Results: Airway fibrosis and remodeling were assessed by measuring TGF-β production and α-SMA deposition. JNJ reduces PAO in WT but not in GILZ KO mice (from 22 ± 1 mm to 15 ± 0.5 and from 24 ± 1.5 to 19 ± 0.5 respectively), MPO activity (from 204 ± 3.13 pmol/mg to 73.88 ± 2.63 in WT and from 221 ± 4.46 pmol/mg to 107 ± 5.54 in GILZ KO), the inflammatory response, TGF-β production, and α-SMA deposition in comparison to WT and GILZ KO vehicle groups. Conclusion: In conclusion, the role of H4 R and GILZ in relation to glucocorticoids could pave the way for innovative therapies to counteract pulmonary fibrosis. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Anti-Inflammatory Effects of Synthetic Peptides Based on Glucocorticoid-Induced Leucine Zipper (GILZ) Protein for the Treatment of Inflammatory Bowel Diseases (IBDs).
- Author
-
Paglialunga, Musetta, Flamini, Sara, Contini, Raffaele, Febo, Marta, Ricci, Erika, Ronchetti, Simona, Bereshchenko, Oxana, Migliorati, Graziella, Riccardi, Carlo, and Bruscoli, Stefano
- Subjects
INFLAMMATORY bowel diseases ,PEPTIDOMIMETICS ,LEUCINE zippers ,LYMPHOCYTE transformation ,PEPTIDES - Abstract
Glucocorticoids (GCs) are commonly used to treat autoimmune and inflammatory diseases, but their clinical effects and long-term use can lead to serious side effects. New drugs that can replace GCs are needed. Glucocorticoid-induced leucine zipper (GILZ) is induced by GCs and mediates many of their anti-inflammatory effects, such as inhibiting the pro-inflammatory molecule NF-κB. The GILZ C-terminal domain (PER region) is responsible for GILZ/p65NF-κB interaction and consequent inhibition of its transcriptional activity. A set of five short peptides spanning different parts of the PER region of GILZ protein was designed, and their anti-inflammatory activity was tested, both in vitro and in vivo. We tested the biological activity of GILZ peptides in human lymphocytic and monocytic cell lines to evaluate their inhibitory effect on the NF-κB-dependent expression of pro-inflammatory cytokines. Among the tested peptides, the peptide named PEP-1 demonstrated the highest efficacy in inhibiting cell activation in vitro. Subsequently, PEP-1 was further evaluated in two in vivo experimental colitis models (chemically induced by DNBS administration and spontaneous colitis induced in IL-10 knock-out (KO) mice (to assess its effectiveness in counteracting inflammation. Results show that PEP-1 reduced disease severity in both colitis models associated with reduced NF-κB pro-inflammatory activity in colon lamina propria lymphocytes. This study explored GILZ-based 'small peptides' potential efficacy in decreasing lymphocyte activation and inflammation associated with experimental inflammatory bowel diseases (IBDs). Small peptides have several advantages over the entire protein, including higher selectivity, better stability, and bioavailability profile, and are easy to synthesize and cost-effective. Thus, identifying active GILZ peptides could represent a new class of drugs for treating IBD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. GILZ Modulates the Recruitment of Monocytes/Macrophages Endowed with a Resolving Phenotype and Favors Resolution of Escherichia coli Infection.
- Author
-
Grossi, Laís C., Zaidan, Isabella, Souza, Jéssica Amanda Marques, Carvalho, Antônio Felipe S., Sanches, Rodrigo C. O., Cardoso, Camila, Lara, Edvaldo S., Montuori-Andrade, Ana Clara M., Bruscoli, Stefano, Marchetti, Maria Cristina, Riccardi, Carlo, Teixeira, Mauro M., Tavares, Luciana P., Vago, Juliana P., and Sousa, Lirlândia P.
- Subjects
PHAGOCYTOSIS ,ESCHERICHIA coli diseases ,MONOCYTES ,MACROPHAGES ,CELL migration ,ESCHERICHIA coli - Abstract
Macrophages are important effectors of inflammation resolution that contribute to the elimination of pathogens and apoptotic cells and restoration of homeostasis. Pre-clinical studies have evidenced the anti-inflammatory and pro-resolving actions of GILZ (glucocorticoid-induced leucine zipper). Here, we evaluated the role of GILZ on the migration of mononuclear cells under nonphlogistic conditions and Escherichia coli-evoked peritonitis. TAT-GILZ (a cell-permeable GILZ-fusion protein) injection into the pleural cavity of mice induced monocyte/macrophage influx alongside increased CCL2, IL-10 and TGF-β levels. TAT-GILZ-recruited macrophages showed a regulatory phenotype, exhibiting increased expression of CD206 and YM1. During the resolving phase of E. coli-induced peritonitis, marked by an increased recruitment of mononuclear cells, lower numbers of these cells and CCL2 levels were found in the peritoneal cavity of GILZ-deficient mice (GILZ
−/− ) when compared to WT. In addition, GILZ−/− showed higher bacterial loads, lower apoptosis/efferocytosis counts and a lower number of macrophages with pro-resolving phenotypes. TAT-GILZ accelerated resolution of E. coli-evoked neutrophilic inflammation, which was associated with increased peritoneal numbers of monocytes/macrophages, enhanced apoptosis/efferocytosis counts and bacterial clearance through phagocytosis. Taken together, we provided evidence that GILZ modulates macrophage migration with a regulatory phenotype, inducing bacterial clearance and accelerating the resolution of peritonitis induced by E. coli. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Association of GILZ with MUC2, TLR2, and TLR4 in Inflammatory Bowel Disease.
- Author
-
Cari, Luigi, Rosati, Lucrezia, Leoncini, Giuseppe, Lusenti, Eleonora, Gentili, Marco, Nocentini, Giuseppe, Riccardi, Carlo, Migliorati, Graziella, and Ronchetti, Simona
- Subjects
INFLAMMATORY bowel diseases ,CROHN'S disease ,ULCERATIVE colitis ,LEUCINE zippers ,DISEASE relapse ,INVERSE relationships (Mathematics) - Abstract
Ulcerative colitis (UC) and Crohn's Disease (CD) are chronic relapsing inflammatory diseases that are caused by genetic, environmental, and immune factors. Treatment strategies are currently based on symptomatic control by immunosuppression. The glucocorticoid-induced leucine zipper (GILZ), a mediator of several effects of glucocorticoids, was recently found to be secreted by goblet cells and play a role in inflammatory bowel disease (IBD). This study investigates which genes GILZ is associated with in its role in intestinal barrier functions. We examined datasets from the Gene Expression Omnibus (GEO) and ArrayExpress profiles of the gut of healthy subjects (HSs), as well as UC and CD patients. The human colonic epithelial HT29 cell line was used for in vitro validation experiments. GILZ was significantly correlated with MUC2, TLR2, and TLR4. In particular, an inverse correlation was found between the GILZ and MUC2 in HS and patients with IBD, mostly in those with an active disease. Further, direct pairwise correlations for GILZ/TLR2 and GILZ/TLR4 were found in HSs and UC patients, but not in CD patients. Overall, our results reveal the crosstalk at the transcription level between the GILZ, MUC2, and TLRs in the mucosal barrier through common pathways, and they open up new perspectives in terms of mucosal healing in IBD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice.
- Author
-
Bruscoli, Stefano, Febo, Marta, Riccardi, Carlo, and Migliorati, Graziella
- Subjects
INFLAMMATORY bowel diseases ,DRUG side effects ,CROHN'S disease ,ANTI-inflammatory agents ,GLUCOCORTICOIDS ,INTESTINAL diseases - Abstract
Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn's disease (CD). IBD etiopathology is multifactorial and involves alteration of immune cells and chronic activation of the inflammatory cascade against yet unknown environmental factors that trigger the disease. IBD therapy aims at improving the quality of life and reducing the risk of disease-related complications to avoid the need for surgery. There is no specific cure for IBDs, and the focus of therapy is supportive measures and use of anti-inflammatory and immunosuppressive drugs. Glucocorticoids (GCs) are powerful anti-inflammatory and immunomodulatory agents used to treat many acute and chronic inflammatory diseases. GCs remain basic treatment for moderate-to-severe IBD, but their use is limited by several important adverse drug effects. Topical administration of a second-generation of GCs, such as budesonide and beclomethasone dipropionate (BDP), represents a valid alternative to use of older, systemic GCs. Administration of second-generation GCs shows promisingly high topical activity and less systemic toxicity, but maintenance therapy with these new GCs in IBD patients is associated with multiple adverse effects. In this review, we make a comparative analysis of the efficacy of first-generation and second-generation GCs in IBD treatment. Unraveling GC biology at the molecular level to uncouple their clinical benefits from detrimental effects is important. One approach is to consider new GC mediators, such as glucocorticoid-induced leucine zipper, which may have similar anti-inflammatory properties, but avoids the side effects of GCs. This in-depth analysis can help to improve the development and the clinical outcomes of GC therapies in IBD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Glucocorticoid-Induced Leucine Zipper: A Novel Anti-inflammatory Molecule.
- Author
-
Bereshchenko, Oxana, Migliorati, Graziella, Bruscoli, Stefano, and Riccardi, Carlo
- Subjects
LEUCINE zippers ,GLUCOCORTICOID receptors ,RECOMBINANT proteins ,TRANSGENIC mice ,KNOCKOUT mice ,INFLAMMATORY bowel diseases - Abstract
Glucocorticoids (GCs) are the most commonly used drugs for treatment of autoimmune and inflammatory diseases. Their efficacy is due to their ability to bind cytoplasmic receptors (glucocorticoid receptors, GR) and other cytoplasmic proteins, thus regulating gene expression. Although GCs are potent life-saving drugs, their therapeutic effects are transitory and chronic use of GCs is accompanied by serious side effects. Therefore, new drugs are needed to replace GCs. We have identified a gene, glucocorticoid-induced leucine zipper (GILZ or tsc22d3), that is rapidly and invariably induced by GCs. Human GILZ is a 135-amino acid protein that mediates many GC effects, including inhibition of the NF-κB and MAPK pathways. Similar to GCs, GILZ exerts anti-inflammatory activity in experimental disease models, including inflammatory bowel diseases and arthritis. While transgenic mice that overexpress GILZ are more resistant, GILZ knockout mice develop worse inflammatory diseases. Moreover, the anti-inflammatory effect of GCs is attenuated in GILZ-deficient mice. Importantly, in vivo delivery of recombinant GILZ protein cured colitis and facilitated resolution of lipopolysaccharide-induced inflammation without apparent toxic effects. A synthetic GILZ-derived peptide, corresponding to the GILZ region that interacts with NF-κB, was able to suppress experimental autoimmune encephalomyelitis. Collectively, these findings indicate that GILZ is an anti-inflammatory molecule that may serve as the basis for designing new therapeutic approaches to inflammatory diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Molecular mechanisms of glucocorticoids: role of GILZ
- Author
-
Riccardi, Carlo and Bruscoli, Stefano
- Subjects
Glucocorticoid ,GILZ - Published
- 2011
9. Caspase-8-dependent post-translational modification of Gilz by Sumo-1
- Author
-
Pozzesi, Nicola, Riccardi, Carlo, and Delfino, Domenico Vittorio
- Subjects
caspase-8 ,gilz ,sumo-1 - Published
- 2009
10. Post-translational modification of Gilz by Sumo-1
- Author
-
Pozzesi, Nicola, Riccardi, Carlo, and Delfino, Domenico Vittorio
- Subjects
thymocyte ,Gilz ,Sumo-1 ,glucocorticoid - Published
- 2009
11. IL-2 induces an altered CD4/CD8 ratio of splenic T lymphocytes from transgenic mice overexpressing thr glucocorticoid-induced protein Gilz
- Author
-
Pozzesi, Nicola, Riccardi, Carlo, and Delfino, Domenico Vittorio
- Subjects
IL-2 ,T lymphocyte ,spleen ,glucocorticoid ,Gilz - Published
- 2007
12. Glucocorticoid-induced leucine zipper overexpression determines a perturbation of thymic subsets by increasing their apoptotic treshold in transgenic mice
- Author
-
Delfino, Domenico Vittorio, Agostini, M., Spinicelli, S., Migliorati, Graziella, and Riccardi, Carlo
- Subjects
glucocrticoids ,gilz ,thymus ,apoptosis ,transgenic mice - Published
- 2003
13. Perturbation of thymic subsets:role of GILZ overexpression in transgenic mice
- Author
-
Delfino, Domenico Vittorio, Agostini, M., Spinicelli, S., Migliorati, Graziella, and Riccardi, Carlo
- Subjects
thymus ,gilz ,glucocorticoids ,transgenic mice ,t lymphocytes - Published
- 2003
14. GILZ as a Mediator of the Anti-Inflammatory Effects of Glucocorticoids.
- Author
-
Ronchetti, Simona, Migliorati, Graziella, Riccardi, Carlo, Cidlowski, John Anthony, and Tliba, Omar
- Subjects
LEUCINE zippers ,ANTI-inflammatory agents ,GLUCOCORTICOIDS - Abstract
Glucocorticoid-induced leucine zipper (GILZ) is a dexamethasone-inducible gene that mediates glucocorticoid (GC) actions in a variety of cell types, including many cells of immune system. In particular, GILZ can control T cell activities, such as activation and differentiation, mainly through its ability to homo- and hetero-dimerize with partner proteins, such as NF-?B, Ras, and C/EBP. These protein-protein interactions control the regulation of pro-inflammatory target genes. A number of in vitro and in vivo studies using mouse models of inflammatory diseases demonstrate an anti-inflammatory role for GILZ. Here, authors summarize the studies that make GILZ eligible as an anti-inflammatory protein through which GCs can act. These findings permit the future development of pharmacological tools that mimic the therapeutic effects of GCs while avoiding the detrimental ones. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. GILZ as a Regulator of Cell Fate and Inflammation.
- Author
-
Bruscoli, Stefano, Riccardi, Carlo, and Ronchetti, Simona
- Subjects
- *
CANCER cells , *HUMAN body , *LEUCINE zippers , *INFLAMMATION , *CELL differentiation , *T cells , *THYMOCYTES , *B cells - Abstract
One of the human body's initial responses to stress is the adrenal response, involving the release of mediators that include adrenaline and glucocorticoids (GC). GC are involved in controlling the inflammatory and immune response mechanisms. Of these, the molecular mechanisms that contribute to anti-inflammatory effects warrant more investigation. Previously, we found that GC induced GILZ (glucocorticoid-induced leucine zipper) quickly and widely in thymocytes, T lymphocytes, and other leukocytes. GILZ regulates the activation of cells and is an essential mediator of endogenous GC and the majority of GC anti-inflammatory effects. Further research in this regard could lead to the development of an anti-inflammatory treatment that yields the therapeutic outcomes of GC but without their characteristic adverse effects. Here, we examine the mechanisms of GILZ in the context of GC. Specifically, we review its role in the proliferation and differentiation of cells and in apoptosis. We also examine its involvement in immune cells (macrophages, neutrophils, dendritic cells, T and B lymphocytes), and in non-immune cells, including cancer cells. In conclusion, GILZ is an anti-inflammatory molecule that could mediate the immunomodulatory activities of GC, with less adverse effects, and could be a target molecule for designing new therapies to treat inflammatory diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. LPS resistance of SPRET/Ei mice is mediated by Gilz, encoded by the Tsc22d3 gene on the X chromosome.
- Author
-
Pinheiro, Iris, Dejager, Lien, Petta, Ioanna, Vandevyver, Sofie, Puimège, Leen, Mahieu, Tina, Ballegeer, Marlies, Van Hauwermeiren, Filip, Riccardi, Carlo, Vuylsteke, Marnik, and Libert, Claude
- Abstract
Natural variation for LPS-induced lethal inflammation in mice is useful for identifying new genes that regulate sepsis, which could form the basis for novel therapies for systemic inflammation in humans. Here we report that LPS resistance of the inbred mouse strain SPRET/Ei, previously reported to depend on the glucocorticoid receptor (GR), maps to the distal region of the X-chromosome. The GR-inducible gene Tsc22d3, encoding the protein Gilz and located in the critical region on the X-chromosome, showed a higher expressed SPRET/Ei allele, regulated in cis. Higher Gilz levels were causally related to reduced inflammation, as shown with knockdown and overexpression studies in macrophages. Transient overexpression of Gilz by hydrodynamic plasmid injection confirmed that Gilz protects mice against endotoxemia Our data strongly suggest that Gilz is responsible for the LPS resistance of SPRET/Ei mice and that it could become a treatment option for sepsis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways.
- Author
-
Ayroldi, Emira, Cannarile, Lorenza, Migliorati, Graziella, Nocentini, Giuseppe, Delfino, Domenico V., and Riccardi, Carlo
- Subjects
GENETIC regulation ,GLUCOCORTICOIDS ,GENOMICS ,MITOGEN-activated protein kinases ,PHYSIOLOGICAL effects of steroid hormones - Abstract
Glucocorticoids (GCs) are steroid hormones produced by the adrenal gland and regulated by the hypothalanms-pituitary-adrenal axis. GCs mediate effects that mostly result in transcriptional regulation of glucocorticoid receptor target genes. Mitogen-activated protein kinases (MAPKs) comprise a family of signaling proteins that convert extracellular stimuli into the activation of intracellular transduction pathways via phosphorylation of a cascade of substrates. They modulate a variety of physiological cell processes, such as proliferation, apoptosis, and development. However, when MAPKs are improperly activated by proinflammatory and/or extracellular stress stimuli, they contribute to the regulation of proinflammatory transcription factors, thus perpetuating activation of the inflammatory cascade. One of the mechanisms by which GCs exert their anti-inflammatory effects is negative interference with MAPK signaling pathways. Several functional interactions between GCs and MAPK signaling have been discovered and studied Some of these interactions involve the GC-mediated up-regulation of proteins that in turn interfere with the activation of MAPK, such as ghicocorticoid-induced-leucine zipper, MAPK phosphatase- 1, and annexin-1. Other mechanisms include activated GR directly interacting with components of the MAPK pathway and negatively regulating their activation. The multiple interactions between GCs and MAP pathways and their potential biological relevance in mediating the anti-inflammatory effects of GCs are reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Glucocorticoid-Induced Leucine Zipper-Mediated TLR2 Downregulation Accounts for Reduced Neutrophil Activity Following Acute DEX Treatment.
- Author
-
Ricci, Erika, Roselletti, Elena, Gentili, Marco, Sabbatini, Samuele, Perito, Stefano, Riccardi, Carlo, Migliorati, Graziella, Monari, Claudia, and Ronchetti, Simona
- Subjects
GLUCOCORTICOIDS ,LEUCINE zippers ,LEUCINE ,DOWNREGULATION ,IMMUNOSUPPRESSIVE agents ,TOLL-like receptors - Abstract
Glucocorticoids are the most powerful anti-inflammatory and immunosuppressive pharmacological drugs available, despite their adverse effects. Glucocorticoid-induced leucine zipper (GILZ) is a glucocorticoid-induced gene that shares several anti-inflammatory properties with glucocorticoids. Although immunosuppressive effects of glucocorticoids on neutrophils remain poorly understood, we previously demonstrated that GILZ suppresses neutrophil activation under glucocorticoid treatment. Here, we sought to explore the regulation of Toll-like receptor 2 (TLR2) by the synthetic glucocorticoid dexamethasone (DEX) on neutrophils and the associated GILZ involvement. Peripheral blood neutrophils were isolated from wild type and GILZ-knock-out (KO) mice. TLR2 was found to be downregulated by the in vivo administration of glucocorticoids in wild type but not in GILZ-KO neutrophils, suggesting the involvement of GILZ in TLR2 downregulation. Accordingly, the TLR2-associated anti-fungal activity of neutrophils was reduced by DEX treatment in wild type but not GILZ-KO neutrophils. Furthermore, GILZ did not interact with NF-κB but was found to bind with STAT5, a pivotal factor in the regulation of TLR2 expression. A similar modulation of TLR2 expression, impaired phagocytosis, and killing activity was observed in circulating human neutrophils treated in vitro with DEX. These results demonstrate that glucocorticoids reduce the ability of neutrophils to respond to infections by downregulating TLR2 via GILZ, thereby reducing critical functions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases.
- Author
-
Vago, Juliana P., Tavares, Luciana P., Riccardi, Carlo, Teixeira, Mauro M., and Sousa, Lirlândia P.
- Subjects
- *
COMMUNICABLE diseases , *INFLAMMATION , *OPPORTUNISTIC infections , *LEUCINE zippers , *ANIMAL models in research , *EMERGING infectious diseases - Abstract
• GILZ and AnxA1 are involved with the anti-inflammatory functions of glucocorticoids without the associated adverse metabolic effects. • GILZ and AnxA1 coordinate the resolution of inflammation and promote host defense in infectious diseases. • GILZ and AnxA1 may be useful pharmacological adjunctive therapies to antibiotics in the context of infectious diseases. For decades, glucocorticoids (GC) have been used to treat several inflammatory conditions, including chronic and autoimmune diseases, due to their potent anti-inflammatory properties. In the context of infectious diseases, the use of GCs may be effective as adjuvant to antibiotic therapy by controlling excessive inflammatory responses resulting in better outcome in some cases. However, the use of GCs has been associated with a vast number of side effects, including increased probability of immunosuppression and consequent risk of opportunistic infection. Glucocorticoid-induced leucine zipper (GILZ) and Annexin A1 (AnxA1) are GC-induced proteins intrinsically involved with the anti-inflammatory functions of GCs without the associated adverse metabolic effects. Recent studies have shown that these GC-proteins exhibit pro-resolving effects. An essential characteristic of pro-resolving molecules is their ability to coordinate the resolution of inflammation and promote host defense in most experimental models of infection. Although the role of GILZ and AnxA1 in the context of infectious diseases remain to be better explored, herein we provide an overview of the emerging functions of these GC-proteins obtained from pre-clinical models of infectious diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Inhibited cell death, NF-κB activity and increased IL-10 in TCR-triggered thymocytes of transgenic mice overexpressing the glucocorticoid-induced protein GILZ
- Author
-
Delfino, Domenico Vittorio, Agostini, Massimiliano, Spinicelli, Stefania, Vacca, Carmine, and Riccardi, Carlo
- Subjects
- *
APOPTOSIS , *CELL death , *TRANSGENIC mice , *GLUCOCORTICOIDS , *LABORATORY mice - Abstract
Abstract: Glucocorticoids promote thymocyte apoptosis and modulate transcription of several genes including GILZ, which is strongly up-regulated in the thymus. We used transgenic mice overexpressing GILZ in the T-cell lineage to investigate TCR-triggered functions of GILZ-overexpressing thymocytes. TCR-triggered apoptosis, but not glucocorticoid-induced apoptosis, was inhibited in transgenic mice compared to their controls. In vivo anti-CD3 administration did not reduce CD4+CD8+ thymocyte number. Analysis of TCR-triggered molecular changes indicated that p65 NF-κB nuclear translocation and DNA binding activity was inhibited in transgenic mice, which might be linked with apoptosis inhibition. IL-10 release increased whereas release of IL-2, IFN-γ, IL-13 and IL-4 remained unchanged. These results support the hypothesis that GILZ regulates, at least in part, T-cell development by influencing thymus function at cellular and molecular levels. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
21. Glucocorticoid-induced leucine zipper modulates macrophage polarization and apoptotic cell clearance.
- Author
-
Vago, Juliana P., Galvão, Izabela, Negreiros-Lima, Graziele L., Teixeira, Lívia C.R., Lima, Kátia M., Sugimoto, Michelle A., Moreira, Isabella Z., Jones, Sarah A., Lang, Tali, Riccardi, Carlo, Teixeira, Mauro M., Harris, James, Morand, Eric F., and Sousa, Lirlândia P.
- Subjects
- *
LEUCINE zippers , *MACROPHAGES , *CHIMERIC proteins , *PHAGOCYTES , *APOPTOSIS , *CELLS - Abstract
Macrophages are professional phagocytes that display remarkable plasticity, with a range of phenotypes that can be broadly characterized by the M1/M2 dichotomy. Glucocorticoid (GC)-induced leucine zipper (GILZ) is a protein known to mediate anti-inflammatory and some pro-resolving actions, including as neutrophil apoptosis. However, the role of GILZ in key macrophage function is not well understood. Here, we investigated the role of GILZ on macrophage reprogramming and efferocytosis. Using murine bone-marrow-derived macrophages (BMDMs), we found that GILZ was expressed in naive BMDMs and exhibited increased expression in M2-like macrophages (IL4-differentiated). M1-like macrophages (IFN/LPS-differentiated) from GILZ-/- mice showed higher expression of the M1 markers CD86, MHC class II, iNOS, IL-6 and TNF-α, associated with increased levels of phosphorylated STAT1 and lower IL-10 levels, compared to M1-differentiated cells from WT mice. There were no changes in the M2 markers CD206 and arginase-1 in macrophages from GILZ-/- mice differentiated with IL-4, compared to cells from WT animals. Treatment of M1-like macrophages with TAT-GILZ, a cell-permeable GILZ fusion protein, decreased the levels of CD86 and MHC class II in M1-like macrophages without modifying CD206 levels in M2-like macrophages. In line with the in vitro data, increased numbers of M1-like macrophages were found into the pleural cavity of GILZ-/- mice after LPS-injection, compared to WT mice. Moreover, efferocytosis was defective in the context of GILZ deficiency, both in vitro and in vivo. Conversely, treatment of LPS-injected mice with TAT-GILZ promoted inflammation resolution, associated with lower numbers of M1-like macrophages and increased efferocytosis. Collectively, these data indicate that GILZ is a regulator of important macrophage functions, contributing to macrophage reprogramming and efferocytosis, both key steps for the resolution of inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.